The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Anna SuredaDuring the 4th European CAR T-cell Meeting the Lymphoma Hub was pleased to speak with, Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain, ES. We asked, Which patients with aggressive B-cell NHL do not qualify for CAR-T? We also asked, Is CAR-T a new standard-of-care for aggressive B-Cell non-hodgkins lymphoma (NHL)
Which patients with aggressive B-cell NHL do not qualify for CAR-T?
Sureda begins by outlining the results of two clinical trials from ASH 2021 that compared SoC followed by allo-HSCT with anti-CD19 CAR T-cell therapy. Sureda expressed that those patients deemed ineligible for treatment with CAR T-cell therapy in these trials would generally not qualify for CAR-T. She goes on to outline a third, less defined group of patients which might not qualify that achieve a complete remission with second line chemotherapy.
Finally Sureda hypothesizes a change in the standard of care for patients with second line aggressive NHL.